KR20250057112A - Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 - Google Patents
Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 Download PDFInfo
- Publication number
- KR20250057112A KR20250057112A KR1020257012376A KR20257012376A KR20250057112A KR 20250057112 A KR20250057112 A KR 20250057112A KR 1020257012376 A KR1020257012376 A KR 1020257012376A KR 20257012376 A KR20257012376 A KR 20257012376A KR 20250057112 A KR20250057112 A KR 20250057112A
- Authority
- KR
- South Korea
- Prior art keywords
- tpa023b
- phosphate
- pain
- polymorph
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862659226P | 2018-04-18 | 2018-04-18 | |
| US62/659,226 | 2018-04-18 | ||
| KR1020207033073A KR102799156B1 (ko) | 2018-04-18 | 2019-04-17 | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 |
| PCT/US2019/027880 WO2019204446A1 (en) | 2018-04-18 | 2019-04-17 | Gabaa positive allosteric modulator compounds, methods of making, and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207033073A Division KR102799156B1 (ko) | 2018-04-18 | 2019-04-17 | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250057112A true KR20250057112A (ko) | 2025-04-28 |
Family
ID=68239798
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020257012376A Pending KR20250057112A (ko) | 2018-04-18 | 2019-04-17 | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 |
| KR1020207033073A Active KR102799156B1 (ko) | 2018-04-18 | 2019-04-17 | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207033073A Active KR102799156B1 (ko) | 2018-04-18 | 2019-04-17 | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11542263B2 (enExample) |
| EP (1) | EP3781566A4 (enExample) |
| JP (3) | JP7449272B2 (enExample) |
| KR (2) | KR20250057112A (enExample) |
| CN (2) | CN121135719A (enExample) |
| AU (2) | AU2019255282B2 (enExample) |
| BR (1) | BR112020021104A2 (enExample) |
| CA (1) | CA3096890A1 (enExample) |
| CL (1) | CL2020002663A1 (enExample) |
| IL (1) | IL278067A (enExample) |
| MX (2) | MX2020010878A (enExample) |
| SG (1) | SG11202010220QA (enExample) |
| TW (1) | TW202012402A (enExample) |
| WO (1) | WO2019204446A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020021104A2 (pt) * | 2018-04-18 | 2021-02-23 | Neurocycle Therapeutics, Inc | compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos |
| CA3132810A1 (en) * | 2019-03-18 | 2020-09-24 | Neurocycle Therapeutics, Inc. | Use of gabaa receptor modulators for treatment of fybromyalgia |
| JP2022553718A (ja) * | 2019-10-22 | 2022-12-26 | ニューロサイクル・セラピューティクス・インコーポレイテッド | Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用 |
| CN120267677A (zh) * | 2019-10-23 | 2025-07-08 | 纽罗塞克医疗公司 | 用gabaa受体调节剂的癫痫状况的治疗 |
| US12233070B2 (en) * | 2020-06-30 | 2025-02-25 | University Of Mississippi Medical Center | Methods for treating benzodiazepine misuse/use disorder |
| JP2025535716A (ja) * | 2022-10-04 | 2025-10-28 | エングレイル セラピューティクス，インコーポレーテッド | Ｇａｂａａ受容体モジュレーターおよびその使用 |
| WO2025175214A1 (en) * | 2024-02-16 | 2025-08-21 | Engrail Therapeutics, Inc. | Methods of treating generalized anxiety disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2802343C2 (de) | 1978-01-20 | 1982-04-22 | Peter Prof. Dr.-Ing. Friderichs | Latentwärmespeicher-Behälter |
| GB9813576D0 (en) * | 1998-06-24 | 1998-08-19 | Merck Sharp & Dohme | Therapeutic agents |
| GB0117277D0 (en) * | 2001-07-16 | 2001-09-05 | Merck Sharp & Dohme | Therapeutic agents |
| CA2427779A1 (en) * | 2000-11-10 | 2002-05-16 | Merck Sharp & Dohme Limited | Imidazo-triazine derivatives as ligands for gaba receptors |
| TWI248936B (en) * | 2001-03-21 | 2006-02-11 | Merck Sharp & Dohme | Imidazo-pyrimidine derivatives as ligands for GABA receptors |
| JP2004170323A (ja) | 2002-11-22 | 2004-06-17 | Sumitomo Pharmaceut Co Ltd | 皮膚疾患治療剤のスクリーニング方法 |
| WO2009021957A2 (en) | 2007-08-14 | 2009-02-19 | Novartis Ag | Tricyclic heterocyclic compounds as gaba a modulators |
| TWI472529B (zh) * | 2008-05-21 | 2015-02-11 | Incyte Corp | ２－氟－Ｎ－甲基－４－〔７－（喹啉－６－基－甲基）－咪唑并〔１，２－ｂ〕〔１，２，４〕三－２－基〕苯甲醯胺之鹽類及其相關製備方法 |
| WO2011011712A1 (en) * | 2009-07-24 | 2011-01-27 | Concert Pharmaceuticals, Inc. | Substituted imidazotriazines |
| AU2014219855B2 (en) | 2013-02-19 | 2017-09-28 | Ono Pharmaceutical Co., Ltd. | Trk-inhibiting compound |
| WO2015072853A1 (en) | 2013-11-13 | 2015-05-21 | Rjg Developments B.V. | Treatment of herpes virus infection outbreaks |
| WO2017129801A1 (en) * | 2016-01-27 | 2017-08-03 | Universität Zürich | Use of gabaa receptor modulators for treatment of itch |
| BR112020021104A2 (pt) * | 2018-04-18 | 2021-02-23 | Neurocycle Therapeutics, Inc | compostos moduladores alostéricos positivos gabaa, métodos de produção e usos dos mesmos |
-
2019
- 2019-04-17 BR BR112020021104-4A patent/BR112020021104A2/pt unknown
- 2019-04-17 CA CA3096890A patent/CA3096890A1/en active Pending
- 2019-04-17 EP EP19788410.9A patent/EP3781566A4/en active Pending
- 2019-04-17 WO PCT/US2019/027880 patent/WO2019204446A1/en not_active Ceased
- 2019-04-17 CN CN202511219750.2A patent/CN121135719A/zh active Pending
- 2019-04-17 TW TW108113441A patent/TW202012402A/zh unknown
- 2019-04-17 SG SG11202010220QA patent/SG11202010220QA/en unknown
- 2019-04-17 CN CN201980041321.7A patent/CN112384513A/zh active Pending
- 2019-04-17 JP JP2021506619A patent/JP7449272B2/ja active Active
- 2019-04-17 AU AU2019255282A patent/AU2019255282B2/en active Active
- 2019-04-17 MX MX2020010878A patent/MX2020010878A/es unknown
- 2019-04-17 KR KR1020257012376A patent/KR20250057112A/ko active Pending
- 2019-04-17 KR KR1020207033073A patent/KR102799156B1/ko active Active
-
2020
- 2020-10-14 MX MX2024004400A patent/MX2024004400A/es unknown
- 2020-10-15 CL CL2020002663A patent/CL2020002663A1/es unknown
- 2020-10-15 IL IL278067A patent/IL278067A/en unknown
- 2020-10-16 US US17/072,282 patent/US11542263B2/en active Active
-
2022
- 2022-12-28 US US18/089,661 patent/US12134619B2/en active Active
-
2024
- 2024-02-29 JP JP2024030150A patent/JP7721712B2/ja active Active
- 2024-10-02 US US18/904,228 patent/US20250034155A1/en active Pending
- 2024-11-07 AU AU2024259803A patent/AU2024259803A1/en active Pending
-
2025
- 2025-07-30 JP JP2025127411A patent/JP2025166011A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020021104A2 (pt) | 2021-02-23 |
| WO2019204446A1 (en) | 2019-10-24 |
| AU2024259803A1 (en) | 2024-11-28 |
| MX2020010878A (es) | 2021-01-29 |
| JP7449272B2 (ja) | 2024-03-13 |
| JP2025166011A (ja) | 2025-11-05 |
| AU2019255282B2 (en) | 2024-08-08 |
| CN112384513A (zh) | 2021-02-19 |
| KR102799156B1 (ko) | 2025-04-21 |
| US11542263B2 (en) | 2023-01-03 |
| US20230139418A1 (en) | 2023-05-04 |
| JP2021522330A (ja) | 2021-08-30 |
| EP3781566A4 (en) | 2022-06-22 |
| CL2020002663A1 (es) | 2021-06-11 |
| IL278067A (en) | 2020-11-30 |
| AU2019255282A1 (en) | 2020-11-05 |
| SG11202010220QA (en) | 2020-11-27 |
| JP2024063136A (ja) | 2024-05-10 |
| US20210040103A1 (en) | 2021-02-11 |
| JP7721712B2 (ja) | 2025-08-12 |
| US20250034155A1 (en) | 2025-01-30 |
| EP3781566A1 (en) | 2021-02-24 |
| MX2024004400A (es) | 2024-04-29 |
| CA3096890A1 (en) | 2019-10-24 |
| TW202012402A (zh) | 2020-04-01 |
| CN121135719A (zh) | 2025-12-16 |
| US12134619B2 (en) | 2024-11-05 |
| KR20210011921A (ko) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102799156B1 (ko) | Gabaa 양성 알로스테릭 조절제 화합물, 이의 제조 방법 및 용도 | |
| CN113646303A (zh) | Fak抑制剂的盐和晶型 | |
| CN119523922A (zh) | 用于口服的包含氨基嘧啶衍生物或其盐的药物组合物 | |
| AU2020364142A1 (en) | Solid state crystalline forms of a selective potassium channel modulator | |
| US12319652B2 (en) | Salts and solid forms of (R)-1-(5-methoxy-1H-indol-1-yl)-N,N-dimethylpropan-2-amine | |
| EP2819998B1 (en) | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1h-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1h-indazol-5-yloxy)benzyl)urea hydrochloride | |
| JP2026021408A (ja) | Ｇａｂａａ陽性アロステリック調節因子化合物、作成方法、およびその使用 | |
| JP2021512118A (ja) | 医薬化合物、その塩、その製剤、ならびにそれらの作製および使用方法 | |
| US12617794B2 (en) | GABAA positive allosteric modulator compounds, methods of making, and uses thereof | |
| EP4660196A1 (en) | Crystal form of compound, preparation method therefor and use thereof | |
| US20230105181A1 (en) | Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A107 | Divisional application of patent | ||
| PA0104 | Divisional application for international application |
Comment text: Divisional Application for International Patent Patent event code: PA01041R01D Patent event date: 20250416 Application number text: 1020207033073 Filing date: 20201117 |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20250509 Comment text: Request for Examination of Application |